Latest news with #BhushanAkshikar
&w=3840&q=100)
Business Standard
01-08-2025
- Business
- Business Standard
GSK Pharma Q1 results: PAT rises 12% to ₹279 cr, income declines marginally
GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to ₹279 crore for the June quarter. The drug firm had reported a net profit of ₹249 crore for the June quarter of the last fiscal. Total income declined marginally to ₹849 crore for the first quarter as compared with ₹850 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. "GSK continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said. The company continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula, he added. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies, Akshikar noted. Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer and Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer. Shares of the company were trading 8.22 per cent down at ₹2,898.40 apiece on BSE. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
News18
01-08-2025
- Business
- News18
GlaxoSmithKline Pharma Q1 net profit rises 12 pc at Rs 279 cr
Agency: New Delhi, Aug 1 (PTI) GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to Rs 279 crore for the June quarter. The drug firm had reported a net profit of Rs 249 crore for the June quarter of the last fiscal. Total income declined marginally to Rs 849 crore for the first quarter as compared with Rs 850 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. 'GSK continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said. The company continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula, he added. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies, Akshikar noted. Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer and Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer. Shares of the company were trading 8.22 per cent down at Rs 2,898.40 apiece on BSE. PTI MSS MSS DR DR view comments First Published: August 01, 2025, 15:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Business Standard
14-05-2025
- Business
- Business Standard
GSK Pharma gains as Q4 PAT rises 35% YoY to Rs 260 cr; declares dividend of Rs 42/share
Glaxosmithkline Pharmaceutical advanced 3.21% to Rs 2,879.70 after the company's standalone net profit jumped 34.73% to Rs 260.14 crore on a 6.06% increase in revenue from operations to Rs 966.08 crore in Q4 FY25 over Q4 FY24. Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same period last year. Total expenses declined 3.53% YoY to Rs 650.64 crore. Notably, the cost of materials consumed dropped 43.65% YoY to Rs 108.35 crore, while employee benefits expense fell 11.49% to Rs 152.97 crore. On a full-year basis, the company's net profit jumped 57.19% to Rs 919.06 crore on a 9.28% rise in revenue to Rs 3,723.49 crore in FY25 over FY24. Bhushan Akshikar, managing director of GlaxoSmithKline Pharmaceuticals, said, Our diversified portfolio of general medicines, specialty, and vaccines has shown improved growth due to sustained innovation, enhanced healthcare professional (HCP) engagement, and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country. The company said it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer, and Jemperli (Dostarlimab), an immunotherapy for second-line treatment of endometrial cancer. Meanwhile, the board recommended a final dividend of Rs 42 per equity share for FY25, subject to shareholder approval at the companys 100th Annual General Meeting. GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.
&w=3840&q=100)
Business Standard
14-05-2025
- Business
- Business Standard
Here's why GSK Pharma share price was buzzing in trade on Wednesday, May 14
GSK Pharma share price: GlaxoSmithKline Pharmaceuticals (GSK Pharma) shares were in demand on Wednesday, May 14, 2025, with the scrip rallying up to 8.46 per cent to hit an intraday high of Rs 3,026.20 per share. At 11:10 PM, however, the GSK Pharma shares were off highs, and were trading 4.18 per cent higher at Rs 906.85 per share. In comparison, BSE Sensex was trading 0.38 per cent higher at 81,460.24 level. What sparked the up move in GSK Pharma share price? The up move in the GSK Pharma share price came after the company posted a healthy March quarter of financial year 2025 (Q4FY25) results. For the quarter ended March 31, 2025 (Q4FY25), GSK Pharma reported a revenue of Rs 966 crore, a like-to-like growth of 6 per cent. The profit after tax (PAT) for the quarter stood at Rs 260 crore. Meanwhile, the company reported full year revenue of Rs 3,723 crore, a growth of 9 per cent from FY24. The PAT before exceptional items (bei) zoomed 32 per cent to Rs 915 crore, and Ebitda margins expanded 500 basis points (bps) to 31.4 per cent. Bhushan Akshikar, managing director, GlaxoSmithKline Pharmaceuticals, said, 'Our diversified portfolio of General Medicines, Specialty, and Vaccines has shown improved growth due to sustained innovation, enhanced Healthcare Professionals (HCP) engagement and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country.' 'We remain committed to delivering sustained above-market growth and strong shareholder returns. In FY2025-26, we will continue to focus on our innovative portfolio through the launch of our oncology assets,' Akshikar added. Furthermore, the company revealed that it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer. GSK Pharma dividend, record date The Board has recommended a final dividend of Rs 42 per equity share on face value of Rs 10 each for the year ended March 31, 2025, subject to approval of members at 100th Annual General Meeting (AGM). The Company has fixed Friday, May 30, 2025, as the 'Record Date' for determining entitlement of members to final dividend for FY25. About GSK Pharma GlaxoSmithKline (GSK) Pharmaceuticals is a global healthcare company specialising in vaccines, specialty medicines, and general medicines. It operates under GSK plc, a British multinational pharmaceutical corporation headquartered in London. GSK India, a subsidiary of GSK plc, is a biopharmaceutical company engaged in the development and marketing of vaccines and medicines, with a strong focus on infectious diseases, HIV, oncology, and immunology.\
